JP2015518904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518904A5 JP2015518904A5 JP2015516260A JP2015516260A JP2015518904A5 JP 2015518904 A5 JP2015518904 A5 JP 2015518904A5 JP 2015516260 A JP2015516260 A JP 2015516260A JP 2015516260 A JP2015516260 A JP 2015516260A JP 2015518904 A5 JP2015518904 A5 JP 2015518904A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- alkoxy
- halo
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 66
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 56
- 125000003118 aryl group Chemical group 0.000 claims description 56
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 125000003282 alkyl amino group Chemical group 0.000 claims description 50
- 125000005843 halogen group Chemical group 0.000 claims description 45
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 42
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 40
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 35
- 125000001424 substituent group Chemical group 0.000 claims description 35
- 125000003545 alkoxy group Chemical group 0.000 claims description 32
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 32
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 23
- 125000001589 carboacyl group Chemical group 0.000 claims description 20
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 18
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 18
- 230000009385 viral infection Effects 0.000 claims description 17
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 16
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 208000036142 Viral infection Diseases 0.000 claims description 12
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000003003 spiro group Chemical group 0.000 claims description 10
- 125000005549 heteroarylene group Chemical group 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- -1 cyano, hydroxy Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000006413 ring segment Chemical group 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 4
- 125000000732 arylene group Chemical group 0.000 claims description 4
- 150000001540 azides Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 4
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims description 4
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
- 229960000329 ribavirin Drugs 0.000 claims description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 208000001490 Dengue Diseases 0.000 claims description 2
- 206010012310 Dengue fever Diseases 0.000 claims description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 201000005807 Japanese encephalitis Diseases 0.000 claims description 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 2
- 201000005805 Murray valley encephalitis Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 241000315672 SARS coronavirus Species 0.000 claims description 2
- 206010041896 St. Louis Encephalitis Diseases 0.000 claims description 2
- 229940124615 TLR 7 agonist Drugs 0.000 claims description 2
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims description 2
- 201000006449 West Nile encephalitis Diseases 0.000 claims description 2
- 208000003152 Yellow Fever Diseases 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
- 229960000517 boceprevir Drugs 0.000 claims description 2
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000025729 dengue disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 2
- 229960002063 sofosbuvir Drugs 0.000 claims description 2
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 229960002935 telaprevir Drugs 0.000 claims description 2
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 claims description 2
- 108010017101 telaprevir Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims 1
- 241000907316 Zika virus Species 0.000 claims 1
- 0 CC(CCCC(NC(C(C(C)[C@](C)C(N1N[C@]2CCC1)=O)=O)=C(C)C)=O)C=C*(C(C1)N)=CC=C1[C@@](C)*C2=O Chemical compound CC(CCCC(NC(C(C(C)[C@](C)C(N1N[C@]2CCC1)=O)=O)=C(C)C)=O)C=C*(C(C1)N)=CC=C1[C@@](C)*C2=O 0.000 description 23
- 150000002148 esters Chemical class 0.000 description 14
- 229940002612 prodrug Drugs 0.000 description 14
- 239000000651 prodrug Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 9
- LURLDFUOIKEELM-NPKGIASISA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c(cc1)nc2c1ccc(/C=C/CCC(CC1)(F)F)c2)=O)=O)=O)NC1=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c(cc1)nc2c1ccc(/C=C/CCC(CC1)(F)F)c2)=O)=O)=O)NC1=O LURLDFUOIKEELM-NPKGIASISA-N 0.000 description 2
- QTYULVDUFLCFOF-NLCONRCSSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(O[C@H](C)c1nc2cc(/C=C/C3(CC4)CCN4C(OC(C)(C)C)=O)ccc2cc1)=O)=O)=O)NC3=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(O[C@H](C)c1nc2cc(/C=C/C3(CC4)CCN4C(OC(C)(C)C)=O)ccc2cc1)=O)=O)=O)NC3=O QTYULVDUFLCFOF-NLCONRCSSA-N 0.000 description 2
- VLMXFTVJDLZBJC-OMCJITFHSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(O[C@H](C)c1nc2cc(/C=C/C34CCNCC3)ccc2cc1)=O)=O)=O)NC4=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(O[C@H](C)c1nc2cc(/C=C/C34CCNCC3)ccc2cc1)=O)=O)=O)NC4=O VLMXFTVJDLZBJC-OMCJITFHSA-N 0.000 description 2
- ZCXNIEBUCYJLPK-AOLLOGBZSA-N CCC[C@](CCOCC)(/C=C/c1ccc(ccc([C@@H](C)OC([C@H](CCC2)NN2C([C@H](C)NC([C@H](C(C)C)N2)=O)=O)=O)n3)c3c1)C2=O Chemical compound CCC[C@](CCOCC)(/C=C/c1ccc(ccc([C@@H](C)OC([C@H](CCC2)NN2C([C@H](C)NC([C@H](C(C)C)N2)=O)=O)=O)n3)c3c1)C2=O ZCXNIEBUCYJLPK-AOLLOGBZSA-N 0.000 description 2
- CHEQYRNYWVIYEI-KGCYQTSASA-N C[C@H](c1nc2cc(/C=C/C(C)(C)C(N[C@@H](/C(/C)=C/C)C(N[C@@H](C)C(N3N[C@H]4CCC3)=O)=O)=O)ccc2cc1)OC4=O Chemical compound C[C@H](c1nc2cc(/C=C/C(C)(C)C(N[C@@H](/C(/C)=C/C)C(N[C@@H](C)C(N3N[C@H]4CCC3)=O)=O)=O)ccc2cc1)OC4=O CHEQYRNYWVIYEI-KGCYQTSASA-N 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- QBNHNFSXZUANPX-PFZJTCDASA-N CC([C@@H](C(N[C@@H](C)C(N(CCC1)NC1C(O[C@H](C)C1C=C(C=C(/C=C/C2)N=C3)C3=CC1)=O)=O)=O)NC2=O)O Chemical compound CC([C@@H](C(N[C@@H](C)C(N(CCC1)NC1C(O[C@H](C)C1C=C(C=C(/C=C/C2)N=C3)C3=CC1)=O)=O)=O)NC2=O)O QBNHNFSXZUANPX-PFZJTCDASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 125000005576 pyrimidinylene group Chemical group 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657550P | 2012-06-08 | 2012-06-08 | |
| US61/657,550 | 2012-06-08 | ||
| PCT/US2013/044826 WO2013185103A1 (en) | 2012-06-08 | 2013-06-07 | Macrocyclic inhibitors of flaviviridae viruses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518904A JP2015518904A (ja) | 2015-07-06 |
| JP2015518904A5 true JP2015518904A5 (enExample) | 2016-07-28 |
| JP6209601B2 JP6209601B2 (ja) | 2017-10-04 |
Family
ID=48692655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516260A Expired - Fee Related JP6209601B2 (ja) | 2012-06-08 | 2013-06-07 | フラビウイルス科ウイルスの大環状阻害剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9145441B2 (enExample) |
| EP (1) | EP2861604B1 (enExample) |
| JP (1) | JP6209601B2 (enExample) |
| KR (1) | KR20150040265A (enExample) |
| CN (1) | CN104703991B (enExample) |
| AU (1) | AU2013270672B2 (enExample) |
| BR (1) | BR112014030630A2 (enExample) |
| CA (1) | CA2875692A1 (enExample) |
| EA (1) | EA026235B1 (enExample) |
| ES (1) | ES2624223T3 (enExample) |
| HK (1) | HK1211285A1 (enExample) |
| IL (1) | IL236005A0 (enExample) |
| IN (1) | IN2014MN02652A (enExample) |
| MX (1) | MX2014014766A (enExample) |
| NZ (2) | NZ724503A (enExample) |
| PL (1) | PL2861604T3 (enExample) |
| PT (1) | PT2861604T (enExample) |
| SG (1) | SG11201408047XA (enExample) |
| SI (1) | SI2861604T1 (enExample) |
| WO (1) | WO2013185103A1 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| SI2859009T1 (sl) * | 2012-06-08 | 2017-12-29 | Gilead Sciences, Inc. | Makrociklični inhibitorji flaviviridae virusov |
| CA2875692A1 (en) | 2012-06-08 | 2013-12-12 | Selcia Limited | Macrocyclic inhibitors of flaviviridae viruses |
| CN118286245A (zh) | 2014-12-26 | 2024-07-05 | 埃莫里大学 | N4-羟基胞苷和衍生物及与其相关的抗病毒用途 |
| KR102394917B1 (ko) | 2015-03-04 | 2022-05-09 | 길리애드 사이언시즈, 인코포레이티드 | 톨 유사 수용체 조정제 화합물 |
| WO2017007892A1 (en) * | 2015-07-07 | 2017-01-12 | Nch Corporation | System and method for treating water with a biological based biocide |
| JP2018525412A (ja) | 2015-08-26 | 2018-09-06 | ギリアード サイエンシーズ， インコーポレイテッド | 重水素化トール様受容体調節因子 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| EP4483875A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| MX2018014377A (es) | 2016-05-27 | 2019-03-14 | Gilead Sciences Inc | Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3). |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| PT3507276T (pt) | 2016-09-02 | 2022-01-11 | Gilead Sciences Inc | Compostos moduladores do recetor de tipo toll |
| MA46535A (fr) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b |
| BR112019015231A2 (pt) | 2017-01-25 | 2020-04-14 | Basf Se | processos para a preparação de compostos e compostos |
| TWI714820B (zh) | 2017-01-31 | 2021-01-01 | 美商基利科學股份有限公司 | 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| EP3601267A1 (en) | 2017-03-21 | 2020-02-05 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN109384727B (zh) * | 2017-08-10 | 2023-07-28 | 中国科学院上海药物研究所 | 酞嗪酮类化合物、其制备方法、药物组合物及用途 |
| JP6934562B2 (ja) | 2017-08-22 | 2021-09-15 | ギリアード サイエンシーズ， インコーポレイテッド | 治療用複素環式化合物 |
| RS66222B1 (sr) | 2017-12-07 | 2024-12-31 | Univ Emory | N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim |
| UA126349C2 (uk) | 2017-12-13 | 2022-09-21 | Люпін Лімітед | Заміщені біциклічні гетероциклічні сполуки як інгібітори prmt5 |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| SI3752501T1 (sl) | 2018-02-13 | 2023-08-31 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| US20220274979A1 (en) | 2018-04-18 | 2022-09-01 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| WO2020010223A1 (en) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| EP3818052A1 (en) | 2018-07-06 | 2021-05-12 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| SI3820572T1 (sl) | 2018-07-13 | 2023-12-29 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| JP7350871B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ２’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| CN114245807B (zh) | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| MY208114A (en) | 2019-09-30 | 2025-04-16 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
| CA3160142A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2021091967A1 (en) * | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN115894606A (zh) | 2019-11-04 | 2023-04-04 | 锐新医药公司 | Ras抑制剂 |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2021198981A1 (en) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Antiviral compounds and uses thereof |
| BR112023002164A2 (pt) | 2020-08-07 | 2023-03-14 | Gilead Sciences Inc | Profármacos de análogos de nucleotídeos de fosfonamida e seu uso farmacêutico |
| KR20230067635A (ko) | 2020-09-15 | 2023-05-16 | 레볼루션 메디슨즈, 인크. | 암의 치료에서 ras 억제제로서 인돌 유도체 |
| EP4214204A1 (en) | 2020-09-18 | 2023-07-26 | Bayer Aktiengesellschaft | Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| CN118852330A (zh) | 2021-05-05 | 2024-10-29 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| TW202348237A (zh) | 2021-05-13 | 2023-12-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
| EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN114634421A (zh) * | 2022-02-24 | 2022-06-17 | 济宁晟泰药业有限公司 | 一种达沙替尼中间体的制备方法 |
| CN120019059A (zh) | 2022-07-29 | 2025-05-16 | 辉瑞公司 | 新型acc抑制剂 |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US20050159345A1 (en) | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
| EP2301937A1 (en) | 2005-06-16 | 2011-03-30 | Cv Therapeutics, Inc. | Prodrugs of A2b adenosine receptor antagonists |
| EP1893211B1 (en) * | 2005-06-17 | 2011-09-14 | Novartis AG | Use of sanglifehrin in hcv |
| EP2011786A1 (en) | 2007-07-05 | 2009-01-07 | Laboratorios del Dr. Esteve S.A. | Indane-amine derivatives, their preparation and use as medicaments |
| CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| WO2009088256A2 (ko) | 2008-01-09 | 2009-07-16 | Konkuk University Industrial Cooperation Corp | 배큘로바이러스-기반 백신 |
| US20100080770A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| JP5687631B2 (ja) * | 2008-12-23 | 2015-03-18 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツドＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｈｃｖのマクロ環状プロテアーゼ阻害剤を製造するための方法および中間体 |
| WO2011063233A1 (en) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| JP5868872B2 (ja) * | 2010-01-15 | 2016-02-24 | ギリアード サイエンシーズ， インコーポレイテッド | フラビウイルス科ウイルスのインヒビター |
| WO2011090935A1 (en) | 2010-01-19 | 2011-07-28 | Merck Sharp & Dohme Corp. | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS |
| WO2011098808A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| GB201008123D0 (en) * | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
| US20130178413A1 (en) * | 2010-09-21 | 2013-07-11 | John A. McCauley | Hcv ns3 protease inhibitors |
| UY33775A (es) * | 2010-12-10 | 2012-07-31 | Gilead Sciences Inc | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos |
| CA2875692A1 (en) | 2012-06-08 | 2013-12-12 | Selcia Limited | Macrocyclic inhibitors of flaviviridae viruses |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| HK1207643A1 (en) | 2012-06-08 | 2016-02-05 | Glenmark Pharmaceuticals S.A. | Amides of 2-amino-4-arylthiazole compounds and their salts |
| SI2859009T1 (sl) * | 2012-06-08 | 2017-12-29 | Gilead Sciences, Inc. | Makrociklični inhibitorji flaviviridae virusov |
-
2013
- 2013-06-07 CA CA2875692A patent/CA2875692A1/en not_active Abandoned
- 2013-06-07 EP EP13731203.9A patent/EP2861604B1/en not_active Not-in-force
- 2013-06-07 WO PCT/US2013/044826 patent/WO2013185103A1/en not_active Ceased
- 2013-06-07 IN IN2652MUN2014 patent/IN2014MN02652A/en unknown
- 2013-06-07 CN CN201380039194.XA patent/CN104703991B/zh not_active Expired - Fee Related
- 2013-06-07 US US13/913,259 patent/US9145441B2/en not_active Ceased
- 2013-06-07 ES ES13731203.9T patent/ES2624223T3/es active Active
- 2013-06-07 PL PL13731203T patent/PL2861604T3/pl unknown
- 2013-06-07 MX MX2014014766A patent/MX2014014766A/es unknown
- 2013-06-07 SG SG11201408047XA patent/SG11201408047XA/en unknown
- 2013-06-07 PT PT137312039T patent/PT2861604T/pt unknown
- 2013-06-07 NZ NZ724503A patent/NZ724503A/en not_active IP Right Cessation
- 2013-06-07 SI SI201330574A patent/SI2861604T1/sl unknown
- 2013-06-07 HK HK15111999.1A patent/HK1211285A1/xx unknown
- 2013-06-07 BR BR112014030630A patent/BR112014030630A2/pt not_active Application Discontinuation
- 2013-06-07 AU AU2013270672A patent/AU2013270672B2/en not_active Ceased
- 2013-06-07 KR KR1020157000171A patent/KR20150040265A/ko not_active Withdrawn
- 2013-06-07 NZ NZ703040A patent/NZ703040A/en not_active IP Right Cessation
- 2013-06-07 EA EA201492209A patent/EA026235B1/ru not_active IP Right Cessation
- 2013-06-07 JP JP2015516260A patent/JP6209601B2/ja not_active Expired - Fee Related
-
2014
- 2014-11-30 IL IL236005A patent/IL236005A0/en unknown
-
2015
- 2015-08-07 US US14/821,458 patent/US9512175B2/en not_active Expired - Fee Related
-
2017
- 2017-09-25 US US15/715,080 patent/USRE47334E1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015518904A5 (enExample) | ||
| JP2015525221A5 (enExample) | ||
| JP2015525220A5 (enExample) | ||
| CN115215914B (zh) | 核苷类似物及其用途 | |
| SI2861601T1 (en) | Macrocyclic flaviviridae virus inhibitors | |
| JP2014503516A5 (enExample) | ||
| RU2468029C2 (ru) | Ингибиторы hcv ns3 протеазы | |
| WO2012092484A3 (en) | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections | |
| JP2013538235A5 (enExample) | ||
| JP2012504126A5 (enExample) | ||
| ES2561888T3 (es) | Derivados de ácido tiofeno-2-carboxílico útiles como inhibidores de virus Flaviviridae | |
| CA2389745A1 (en) | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues | |
| JP2017505314A5 (enExample) | ||
| JP2008531704A5 (enExample) | ||
| JP2007534662A5 (enExample) | ||
| JP2013514359A5 (enExample) | ||
| RU2015123641A (ru) | 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний | |
| JP2012523415A5 (enExample) | ||
| JP2012513479A5 (enExample) | ||
| JP2011523651A5 (enExample) | ||
| RU2011133900A (ru) | Аналоги циклоспорина для предупреждения или лечения инфекции гепатита с | |
| JP2016503800A5 (enExample) | ||
| MXPA04007876A (es) | Analogos de nucleosido fluorado modificados. | |
| JP2014532716A5 (enExample) | ||
| JP2014514308A5 (enExample) |